<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/214103-pharmaceutical-composition-for-the-treatment-of-diseases-caused-by-thrombus-or-embolus by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 07:28:04 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 214103:PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DISEASES CAUSED BY THROMBUS OR EMBOLUS.</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DISEASES CAUSED BY THROMBUS OR EMBOLUS.</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>Medicinal compositions containing as the active ingredients 2-acetoxy-5- .-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or its pharmacologically acceptable salt and aspirin. Because of having excellent inhibitory effects on platelet aggregation and thrombosis, these compositions are useful as preventives or remedies for diseases induced by thrombus or embolization.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>SPECIFICATION<br>
PHARMACEUTICAL COMPOSITION COMPRISING ASPIRIN<br>
[TECHNICAL FIELD]<br>
This invention relates to pharmaceutical compositions containing 2-<br>
acetoxy- 5- (a-cyclopropylcarbonyl-2 fluorobenzyl) - 4,5,6,7-tetrahydrothieno[3,2 -<br>
clpyridine or a pharmaceutically acceptable salt thereof, and aspirin, as active<br>
ingredients [particularly pharmaceutical compositions for prevention or<br>
treatment (particularly for treatment) of diseases caused by thrombus or<br>
embolus]; to the use of 2-acetoxy-5-(a-cyclopropylcarbonyl-2-fluorobenzyl)-<br>
4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt<br>
thereof and aspirin for the manufacture of pharmaceutical compositions for<br>
prevention or treatment (particularly for treatment) of diseases caused by<br>
thrombus or embolus; and to methods for the prevention or treatment<br>
(particularly to methods for the treatment) of diseases caused by thrombus or<br>
embolus by administration of an effective amount of 2-acetoxy-5-(a-<br>
cyclopropylcarbonyl-2-fluoroben2yl)-4,5,6,7-tetxahydrothieno[3,2-c]pyridine or a<br>
pharmaceutically acceptable salt thereof and aspirin to warm-blooded animals<br>
(particularly humans).<br>
[BACKGROUND ART]<br>
2-Acetoxy-5- (a-cyclopropylcarbonyl-2 -fluorobenzyl) -4,5,6,7-<br>
tetrahydrothieno[3,2-c]pyridine has been described in the Japanese Patent<br>
Application Publication No. Hei 6-41139, and possesses potent inhibitory<br>
activity against platelet aggregation. Furthermore, aspirin is well known to have<br>
an inhibiting activity against platelet aggregation, although the activity is low.<br>
However, pharmaceutical compositions containing both compounds have not<br>
been known.<br>
[DISCLOSURE OF THE INVENTION]<br>
The present inventors have studied therapeutic agents with low toxicity<br>
that exert inhibitory activity against platelet aggregation and have found that the<br>
problems described above are solved by using pharmaceutical compositions<br>
comprising 2- acetoxy- 5- (a- cyclopropylcarbonyl-2- fluorobenzyl)-4,5,6,7-<br>
tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof<br>
and aspirin.<br>
The present invention provides pharmaceutical compositions containing<br>
2-acetoxy-5-(a-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-<br>
c]pyridine or a pharmaceutically acceptable salt thereof and aspirin as active<br>
ingredients [particularly pharmaceutical compositions for prevention or<br>
treatment (particularly for treatment) of diseases caused by thrombus or<br>
embolus]; the use of 2-acetoxy-5-(a-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-<br>
tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof,<br>
and aspirin, for the manufacture of pharmaceutical compositions [particularly<br>
pharmaceutical compositions for prevention or treatment (particularly for<br>
treatment) of diseases caused by thrombus or embolus]; and methods for the<br>
prevention or treatment (particularly methods for treatment) of diseases caused<br>
by thrombus or embolus by administration of an effective amount of 2-acetoxy-<br>
5-(a-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine<br>
or a pharmaceutically acceptable salt thereof, and aspirin, to warm-blooded<br>
animals (particularly humans), simultaneously or sequentially.<br>
2-Acetoxy-5-(a-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-<br>
tetrahydrothieno[3,2-c]pyridine, and pharmaceutically acceptable salts thereof,<br>
which is one of the active ingredients of the present invention, is a known<br>
compound. For instance, the compound has already been described in<br>
Japanese Patent Application Publication No. Hei 6-41139 and Japanese Patent<br>
Application Publication No. 2002-145883 (priority: Japanese Patent Application<br>
No. 2000-205396 and Japanese Patent Application No. 2000-266780). The<br>
chemical structure is described below.<br>
The pharmaceutically acceptable salts of 2-acetoxy-5-(a-<br>
cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine may<br>
be, for example, hydrohalogenic acid salts such as hydrofluoride, hydrochloride,<br>
hydrobromide or hydroiodide; nitrate; perchlorate; sulfate; phosphate; C1-C4<br>
alkanesulfonates optionally substituted by halogens such as methanesulfonate,<br>
trifluoromethanesulfonate, ethanesulfonate; C6-C10 arylsulfonates optionally<br>
substituted by C1-C4 alkyl groups such as benzenesulfonate or p-<br>
toluenesulfonate; C1-C6 aliphatic acid salts such as acetate, malate, fumarate,<br>
succinate, citrate, tartarate, oxalate or maleate; amino acid salts such as glycine<br>
salt, lysine salt, arginine salt, ornitine salt, glutamic acid salt or aspartic acid<br>
salt; and the preferred compounds are hydrohalogenates or C1-C6 aliphatic acid<br>
salts; and more preferred compounds are the hydrochloride or the maleate.<br>
When one of the active ingredients of the present invention, 2-acetoxy-5-<br>
(a-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or<br>
a pharmaceutically acceptable salt thereof, is allowed to stand so that it is open<br>
to the atmosphere, it may become hydrated by absorption of water or adsorption<br>
of water. Such hydrated compounds are included in the present invention.<br>
Further, one of the active ingredients of the present invention, 2-acetoxy-<br>
5-(a-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine<br>
or a pharmaceutically acceptable salt thereof, may absorb some kinds of organic<br>
solvents and may form solvates in some cases, and these solvates are also<br>
included in the present invention.<br>
Furthermore, since 2-acetoxy-5-(a-cyclopropylcarbonyl-2-fluorobenzyl)-<br>
4,5,6,7-tetrahydrothieno[3,2-c]pyridine has an asymmetric carbon atom, optical<br>
isomers exist based on the asymmetric carbon atom. These optical isomers are<br>
also included in the present invention.<br>
The other active ingredient, aspirin, is a well-known compound, as an<br>
analgesic antipyretic.<br>
[INDUSTRIAL APPLICABILITY]<br>
The pharmaceutical compositions of the present invention (particularly<br>
pharmaceutical compositions for the prevention or treatment of diseases caused<br>
by thrombus or embolus) which contain 2-acetoxy-5-(a-cyclopropylcarbonyl-2-<br>
fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically<br>
acceptable salt thereof, and aspirin, as active ingredients, possess excellent<br>
inhibitory activity against platelet aggregation and thrombogenesis with short<br>
onset latency and low toxicity. Thus the pharmaceutical compositions of the<br>
present invention are useful as preventative or therapeutic agents (particularly<br>
as therapeutic agents) against diseases caused by thrombus or embolus, for<br>
example, diseases induced by platelet aggregation, including stable or unstable<br>
angina pectoris and so forth; cardiovascular or cerebrovascular disorders, e.g.,<br>
thromboembolism, associated with atherosclerosis or diabetes mellitus, such as<br>
unstable angina pectoris, cerebral ischemic insult or restenosis due to<br>
angioplasty, endarterectomy or stent therapy; or thromboembolism caused by<br>
thromboembolization such as recurrent embolism after degradation of the<br>
original thrombus, embolism, ischemia-induced dementia, peripheral<br>
arteriopathy, thromboembolization associated with hemodialysis or atrial<br>
fibrillation, or thromboembolization in the vascular prosthesis, or in the bypass<br>
between the aorta and the coronary artery. Furthermore, the therapeutic agent<br>
of the present invention is administered to warm-blooded animals (particularly<br>
humans).<br>
According, to the present invention, the use in combination of 2-acetoxy-<br>
5-(a-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine<br>
or a pharmaceutically acceptable salt thereof, and aspirin, results in more<br>
potent effectiveness than the use of each component alone. Furthermore,<br>
plasma levels of these agents do not have to be maintained at a certain level and<br>
higher during the same period, in order to produce their effects. It is believed<br>
that these 2 agents reach the receptors, at which they act in vivo, and turn on<br>
switches at the receptors to induce the effects. Even though the plasma level of<br>
one component of the pharmaceutical composition is too low to induce the<br>
effects with increasing time after the agent was administered, the switches at<br>
the receptors have already been turned on. Thus the preventative or therapeutic<br>
efficacy of the agent is expected by inhibiting thrombogenesis or embolization.<br>
Therefore, when the other component of the pharmaceutical composition<br>
is administered later, the therapeutic effect of the compound administered later<br>
is expected to add to the therapeutic effects of the previously administered<br>
component. However, it is convenient clinically that both components are<br>
administered at the same time. Thus 2-acetoxy-5-(a-cyclopropylcarbonyl-2-<br>
fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically<br>
acceptable salt thereof and aspirin are simultaneously administered as a<br>
combination drug. In the case that both agents cannot be mixed technically,<br>
each component can be administered separately. Moreover, as described<br>
previously, since each component produces significant effects as a single form,<br>
each component can be sequentially administered at appropriate intervals. The<br>
maximum intervals between administration of each of the two components that<br>
can be accepted to elicit significant effects could be confirmed by clinical trials<br>
or animal studies.<br>
The route for administration of 2-acetoxy-5-(a-cyclopropylcarbonyl-2-<br>
fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically<br>
acceptable salt, thereof, and aspirin, which is employed in the present invention,<br>
is generally the oral route. However, other routes, for example, intravenous<br>
administration, can be used. Thus, the 2 components can be prepared<br>
respectively as separate formulations, or can be mixed physically to form a<br>
single formulation for administration. The single formulations of the mixed<br>
components are, for example, powders, granules, tablets, capsules and so forth,<br>
and can be prepared by regular formulation techniques, as described below.<br>
These formulations are prepared by conventional methods by using<br>
excipients (organic excipients, for example, sugar derivatives such as lactose,<br>
sucrose, glucose, mannitol or sorbitol; starch derivatives such as corn starch,<br>
potato starch, a-starch or dextrin; cellulose derivatives such as crystalline<br>
cellulose; gum arabic; dextran; or pullulan; and inorganic excipients, for<br>
example, silicate derivatives such as light silicic acid anhydride, synthetic<br>
aluminum silicate, calcium silicate or magnesium aluminate metasilicate;<br>
phosphate derivatives such as calcium hydrogenphosphate; carbonates such as<br>
calcium carbonate; or sulfates such as calcium sulfate), lubricants (for example,<br>
stearic acid; metal stearate derivatives such as calcium stearate or magnesium<br>
stearate; talc; waxes such as beeswax or spermaceti; boric acid; adipic acid;<br>
sulfate derivatives such as sodium sulfate; glycol; fumaric acid; sodium<br>
benzoate; DL-leucine; lauryl sulfate derivatives such as sodium lauryl sulfate or<br>
magnesium lauryl sulfate; silicic acid derivatives such as silicic acid anhydride<br>
or silicic acid hydrate; and starch derivatives described above), binders (for<br>
example, hydroxypropyl cellulose, hydroxypropylmethylcellulose,<br>
poly(vinylpyrrolidone), polyethylene glycol and similar compounds described in<br>
the above excipients), disintegrators (for example, cellulose derivatives such as<br>
low substituted hydroxypropylcellulose, carboxymethylcellulose, calcium<br>
carboxymethylcellulose, internally cross-linked sodium carboxymethylcellulose;<br>
chemically modified starch/cellulose derivatives such as carboxymethylstarch,<br>
sodium carboxymethylstarch; cross-linked polyvinylpyrrolidone; or starch<br>
derivatives described above), emulsifiers (for example, colloidal clays such as<br>
bentonite or veegum; metal hydroxides such as magnesium hydroxide or<br>
aluminum hydroxide; anionic surfactants such as sodium lauryl sulfate or<br>
calcium stearate; cationic surfactants such as benzalkonium chloride; or<br>
nonionic surfactants such as polyoxyethylene alkyl ether,<br>
polyoxyethylenesorbitan ester of fatty acids or sucrose ester of fatty acids),<br>
stabilizers (for example, parahydroxybenzoates such as methylparaben or<br>
propylparaben; alcohols such as chlorobutanol, benzyl alcohol or phenylethyl<br>
alcohol; benzalkonium chlorides; phenol derivatives such as phenol or cresol;<br>
thimerosal; dehydroacetic acid; or sorbic acid), aorrigents (for example,<br>
sweetening, souring and flavoring agents all of which are conventionally used),<br>
and diluents.<br>
The dose and the dose ratio of 2-acetoxy-5-(a-cyclopropylcarbonyl-2-<br>
fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or pharmaceutically<br>
acceptable salt thereof, and aspirin, can be widely altered based on several<br>
factors such as activity of each compound, and the symptoms, age and body<br>
weight of the patients.<br>
Generally, the lower limit of the oral dose (mg drug dose/time) is 0.1 mg<br>
(preferably, 1 mg) per time, while the upper limit is 1,000 mg (preferably, 500<br>
mg) per time. The lower and upper limits of intravenous injection are 0.01 mg<br>
(preferably, 0.1 mg) and 500 mg (preferably, 250 mg), respectively. They are<br>
administered to the adult from 1 to 7 times a day based on the symptoms of the<br>
patient, simultaneously or sequentially.<br>
Generally, the dose ratio of 2-acetdxy-5-(a-cyclopropylcarbonyl-2-<br>
fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or pharmaceutically<br>
acceptable salt thereof, and aspirin, is from 1:500 to 500:1 as their weight ratio.<br>
[Best Mode for Carrying Out the Invention]<br>
The present invention is described in detail with examples and<br>
formulations in the following. However, the claim of the present invention is not<br>
restricted to the following description.<br>
(Example 1)<br>
Inhibitory Activity against Thrombogenesis<br>
As the test animals, male Sprague Dawley rats of 7 weeks old were<br>
purchased from SLC Japan and 6 rats per group were used.<br>
2-Acetoxy-5-(a-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-<br>
tetrahydrothieno[3,2-c]pyridine was synthesized according to the method<br>
described in the Specification of Japanese Patent Application Publication No. Hei<br>
6-41139 and was used, while aspirin was purchased from Sigma Chemical Co.<br>
and was used. Both compounds were suspended in 5% (w/v) gum arabic<br>
solution, and were diluted so as to be 1 ml/kg of administration volume and<br>
were orally administered.<br>
The inhibitory activities of the compounds against thrombogenesis or<br>
thrombus formation were evaluated in the modified arterio-venous shunt<br>
thrombosis model in rats, which was described by Umetsu et al. [Thromb.<br>
Haemost.. 39, 74-83 (1978)].<br>
The shunt tube was prepared as follows; i.e., both sides of a medical<br>
silicon tube of 12 cm length [inner diameter: 1.5 mm, outer diameter: 2.5 mm,<br>
purchased from KANEKA Medix Co., Ltd] were connected each to a polyethylene<br>
tube of 7 cm length [inner diameter: 0.5 mm, outer diameter: 1.0 mm,<br>
purchased from Natsume Seisakusho Co., Ltd.] covered with silicon via a<br>
medical silicon tube of 0.7 cm length [inner diameter: 1.0 mm, outer diameter:<br>
1.5 mm, KANEKA Medix Co., Ltd] as connector. A surgical suture of 10 cm<br>
length was placed in the silicon tube of 12 cm length.<br>
The animal was anesthetized with an intraperitoneal injection of 40<br>
mg/kg of pentobarbital sodium (purchased from Abbott Laboratories Inc.), and<br>
the jugular of one side and the carotid of the other side were exposed. The<br>
arteriovenous shunt was made by cannulation of a shunt tube filled with<br>
heparin solution [30 units/kg, purchased from Fuso Pharmaceutical Co., Ltd]<br>
into the carotid and the jugular which had been previously exposed.<br>
The test compounds were orally administered and the blood was started<br>
to circulate into the shunt area two hours after the administration. Thirty<br>
minutes after the circulation was started, the shunt tube was removed, and the<br>
thrombus adsorbed on the surgical suture was weighed. The results are shown<br>
in Table 1. The results in the table are expressed as the average weight Â± SE<br>
(n=6).<br>
The powders in the formula described in the above table are mixed,<br>
compressed with a tableting machine and formulated as a tablet containing 250<br>
mg in total. The tablet can be coated with film or sugar, when necessary.<br>
WE CLAIM:<br>
1. A pharmaceutical composition comprising 2-acetoxy-6-(a-<br>
cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine<br>
or a pharmaceuticaily acceptable salt thereof, and aspirin, as active<br>
ingrodients.<br>
2. A pharmaceutical composition as claimed in claim 1, in which the<br>
pharmaceuticaily acceptable salt is the hydrochloride or mateate.<br>
3. A idt comprising 2-acetoxy-5-(a-cyclopropylcarbonyl-2-fluorobenzyl)-<br>
4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically a acceptable<br>
salt thereof, and aspirin, for simultaneous or sequential administration.<br>
4. A kit as claimed in claim 3, for simultaneous administration.<br>
5. A ldt as claimed In claim 3, for sequential administration.<br>
6. A kit according to any of claims 3 to 5, in which the pharmaceuticaily<br>
acceptable salt is the hydrochloride or maleate.<br>
Pharmaceutical compositions comprising 2-acetoxy-5-(a-<br>
cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a<br>
pharmaceutically acceptable salt thereof, and aspirin, as active ingredients.<br>
The pharmaceutical compositions of the present invention possess<br>
excellent inhibitory activity against platelet aggregation and thrombogenesis,<br>
and are useful for preventing or treating diseases caused by thrombus or<br>
embolus.</td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
		<br>
		<div class="pull-left">
			<a href="214102-tensioner.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="214104-vitronectin-receptor-antagonist-pharmaceuticals.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>214103</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>777/KOLNP/2003</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>05/2008</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>01-Feb-2008</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>30-Jan-2008</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>13-Jun-2003</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>SANKYO COMPANY LIMITED</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>5-1, NIHONBASHI HONCHO 3-CHOME, CHUO-KU, TOKYO 103-8426</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>ASAI FUMITOSHI</td>
											<td>C/O. SANKYO CO. LTD., 2-58 HIROMACHI 1-CHOME, SHINAGAWA-KU, TOKYO 140-8710,</td>
										</tr>
										<tr>
											<td>2</td>
											<td>SUGIDACHI, ATSUHIRO</td>
											<td>C/O. SANKYO CO. LTD., 2-58, HIROMACHI 1-CHOME, SHINAGAWA-KU, TOKYO 140-8710</td>
										</tr>
										<tr>
											<td>3</td>
											<td>OGAWA, TAKETOSHI</td>
											<td>C/O. SANKYO CO. LTD., 2-58, HIROMACHI 1-CHOME, SHINAGAWA-KU, TOKYO 140-8710</td>
										</tr>
										<tr>
											<td>4</td>
											<td>INOUE TERUHIKO</td>
											<td>C/O. UBE RESEARCH LABORATORY, 1978-5, O-AZA KOGUSHI, YAMAGUCHI 755-0067</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>A61K 31/4365</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/JP01/11201</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2001-12-20</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>2000-392983</td>
									<td>2000-12-25</td>
								    <td>Japan</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/214103-pharmaceutical-composition-for-the-treatment-of-diseases-caused-by-thrombus-or-embolus by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 07:28:05 GMT -->
</html>
